Open AccessModern views on immunological biomarkers of colon cancer
Author(s) -
А. А. Трякин,
Г. Г. Хакимова,
Т. Н. Заботина,
А А Борунова,
О. А. Малихова
Publication year - 2019
Publication title -
zlokačestvennye opuholi
Language(s) - English
Resource type - Journals
eISSN - 2587-6813
pISSN - 2224-5057
DOI - 10.18027/2224-5057-2018-8-4-50-58
Subject(s) - atezolizumab , nivolumab , pembrolizumab , medicine , colorectal cancer , immunotherapy , mechanism (biology) , cancer , oncology , immune system , immunology , philosophy , epistemology
The article briefly describes the mechanism of action of immunotherapeutic drugs that suppress the activity of “checkpoints” of the immune response CTLA-4 and PD-1. Modern methods of clinical efficacy and advantages of applying nivolumab, pembrolizumab and atezolizumab in colorectal cancer. The existing evidence base of the potential predictive and prognostic role of MSI status is summarized and presented information on the prospects for the further development of this therapeutical treatment of malignant tumors.